{"DataElement":{"publicId":"6384241","version":"1","preferredName":"Myeloproliferative Neoplasm Blast Count Greater Than Twenty Assessment Code","preferredDefinition":"A code that  represents the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages the number of blast cells blasts as a percentage of greater than 20  present in a blood sample.","longName":"MNP_BLT_GRT_THN_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6384215","version":"1","preferredName":"Myeloproliferative Neoplasm Blast Count Assessment","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)_The determination of the number of blast cells present in a blood sample._The final result of a determination of the value, significance, or extent of.","longName":"2674375v1.0:6384213v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2674375","version":"1","preferredName":"Chronic Myeloproliferative Disorder","preferredDefinition":"Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults.  -- 2003","longName":"C4345","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"383B5884-C0F0-59CB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-21","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-21","modifiedBy":"ONEDATA","dateModified":"2007-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6384213","version":"1","preferredName":"Blast Count Assessment","preferredDefinition":"The determination of the number of blast cells present in a blood sample.:The final result of a determination of the value, significance, or extent of.","longName":"C74605:C25367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blast Count","conceptCode":"C74605","definition":"The determination of the number of blast cells present in a biospecimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C7FF1A-291D-344B-E053-F662850A067A","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C7FF1A-292E-344B-E053-F662850A067A","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6384234","version":"1","preferredName":"Greater ThanTwenty Myeloproliferative Neoplasm Code","preferredDefinition":"A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status._A natural number greater than nineteen and less than twenty-one and the quantity that it denotes._A condition or state at a particular time.._The final result of a determination of the value, significance, or extent of._A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status._A natural number greater than nineteen and less than twenty-one and the quantity that it denotes._A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)_A symbol or combination of symbols which is assigned to the members of a collection.","longName":"6384234v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"AC","valueDescription":"Acute Leukemia Response Complete","ValueMeaning":{"publicId":"6384236","version":"1","preferredName":"Acute Leukemia Response Complete","longName":"6384236","preferredDefinition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).: Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.: To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia","conceptCode":"C9300","definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete","conceptCode":"C25250","definition":"To possess every necessary or normal part or component or step; having come or been brought to a conclusion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72CB0DB2-5C7C-48B6-E053-F662850A608E","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C81D8A-9378-33E6-E053-F662850AEAC9","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"AP","valueDescription":"Acute Leukemia Response Partial","ValueMeaning":{"publicId":"6384235","version":"1","preferredName":"Acute Leukemia Response Partial","longName":"6384235","preferredDefinition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).: Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.: Being or affecting only a part of something.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia","conceptCode":"C9300","definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Response","conceptCode":"CS050764","definition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Partial","conceptCode":"C25378","definition":"Being or affecting only a part of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72CB0DB2-5C55-48B6-E053-F662850A608E","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C81D8A-938C-33E6-E053-F662850AEAC9","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"CC","valueDescription":"Cytogenetic Complete Response","ValueMeaning":{"publicId":"5508164","version":"1","preferredName":"Cytogenetic Complete Response","longName":"5508164","preferredDefinition":"The disappearance of all signs of cancer, including the absence of a detectable disease-related genetic abnormality, as determined by techniques such as karyotyping or FISH, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Complete Response","conceptCode":"C123578","definition":"The disappearance of all signs of cancer, including the absence of a detectable disease-related genetic abnormality, as determined by techniques such as karyotyping or FISH, in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4A5C62-66C7-5C40-E053-F662850A331B","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C81D8A-93A0-33E6-E053-F662850AEAC9","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"CM","valueDescription":"Molecular Complete Response","ValueMeaning":{"publicId":"5508160","version":"1","preferredName":"Molecular Complete Response","longName":"5508160","preferredDefinition":"The disappearance of all signs of cancer, supported by molecular analysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Molecular Complete Response","conceptCode":"C123593","definition":"The disappearance of all signs of cancer, supported by molecular analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4A5C62-667B-5C40-E053-F662850A331B","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C81D8A-93B4-33E6-E053-F662850AEAC9","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"PD","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"3284666","version":"1","preferredName":"Progressive Disease","longName":"3284666v1.00","preferredDefinition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD9FC7D6-531D-BE97-E040-BB89AD437875","latestVersionIndicator":"Yes","beginDate":"2011-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-23","modifiedBy":"MMADDINENI","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2023.5.17 Alt VM added per ticket request CADSR0002435. ak \r\n2023.3.15 Per LS at COG Protocol defined progressive disease (should have been added as a VM Alt Name for PV 3284666). ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C81D8A-93BE-33E6-E053-F662850AEAC9","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"SD","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2982985","version":"1","preferredName":"Stable Disease","longName":"2982985","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0176-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C81D8A-93D2-33E6-E053-F662850AEAC9","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6384252","version":"1","preferredName":"Greater Than Twenty Myeloproliferative Neoplasm Code","preferredDefinition":"A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.:A natural number greater than nineteen and less than twenty-one and the quantity that it denotes.:A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008):A symbol or combination of symbols which is assigned to the members of a collection.","longName":"C61584:C105799:C4345:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Greater Than","conceptCode":"C61584","definition":"A statement about the relative size or order of two objects specifying that an object of interest exceeds another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Twenty","conceptCode":"C105799","definition":"A natural number greater than nineteen and less than twenty-one and the quantity that it denotes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C81D8A-92D5-33E6-E053-F662850AEAC9","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72CB0DB2-5C0F-48B6-E053-F662850A608E","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is the patient's disease","type":"Preferred Question Text","description":"What is the patient's disease response for this assessment per revised MPN criteria in section 11.2 table 1(if blasts greater than 20% at baseline)?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Assessment per revised MPN criteria if blasts greater than 20 percent at baseline","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72CA8836-D475-4CA3-E053-F662850A170E","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"SOKKERL","dateModified":"2019-04-30","changeDescription":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}